A Prospective Non-Interventional Study to Assess Long-term Effectiveness of Zomacton® and Factors Affecting Adherence in Patients With Growth Hormone Deficiency or Growth Retardation Due to Ullrich-Turner Syndrome
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- Acronyms RAZANT
- Sponsors Ferring Pharmaceuticals
- 12 Oct 2017 Planned initiation date changed from 31 Oct 2017 to 30 Nov 2017.
- 20 Sep 2017 Planned initiation date changed from 15 Sep 2017 to 31 Oct 2017.
- 12 Sep 2017 New trial record